We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

CHEMBIO DIAGNOSTIC SYSTEMS

Chembio develops, manufactures and commercializes diagnostic solutions and products for the rapid and early detection... read more Featured Products: More products

Download Mobile App





Chembio Diagnostics Showcases New DPP Line of Rapid Tests at MEDICA 2019

By LabMedica International staff writers
Posted on 19 Nov 2019
Chembio Diagnostics (Medford, NY, USA) showcased its new DPP line of rapid tests, including DPP Syphilis Screen and Confirm; DPP HIV 1-2 Screen; and, for the global market, DPP Syphilis/HIV combo, the MEDICA 2019 International Trade Fair on November 18-21 in Düsseldorf, Germany. More...
In addition, the company presented its legacy product line of HIV 1-2 SURE CHECK, HIV 1-2 STAT-PAK, HIV 1-2 STAT-PAK Dipstick, as well as its line of unique animal TB diagnostic products.

The MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals. The event drew over 6,000 exhibitors from 70 countries and 120,000 trade visitors from over 170 countries.

Chembio is a leading Point-of-Care (POC) diagnostics company that focuses on detecting and diagnosing infectious diseases. The company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes.

At the 2019 edition of MEDICA, Chembio showcased its DPP Syphilis Screen and Confirm Assay (CE Marked), a rapid POC test that simultaneously and separately detects treponemal and nontreponemal antibodies. Since it screens and confirms syphilis infection simultaneously, there is no need for reflex testing and it does not require specialized medical training. It provides results in as little as 15 minutes, enabling physicians to make treatment decisions, while reducing overtreatment rate and cost burden by eliminating repeated visits to healthcare professionals.

Chembio also showcased its DPP HIV 1-2 Screen Assay, a CLIA-waived test for the rapid detection of HIV 1 and HIV 2 antibodies in oral fluid and all blood matrices. It is intended for use as a POC test to aid in the diagnosis of infection with HIV 1 and HIV 2 and is suitable for use in multi-test algorithms that have been established in many countries or as a standalone initial test. For the global market, Chembio showcased its DPP Syphilis/HIV Combo Assay, the first dual HIV 1/2 and Syphilis POC test based on its DPP technology platform. It is a single-use, immunochromatographic, rapid test for the detection of antibodies to Human Immunodeficiency Virus Types 1 and 2 (HIV 1/2) and Treponema pallidum (the causative agent of syphilis) in fingerstick whole blood, venous whole blood, serum, and plasma. A unique feature of this kit is Chembio’s new DPP SampleTainer bottle which contains a pre-measured dilution buffer within a closed vial that also serves as a dropper for performing the assay.

In addition, Chembio showcased its legacy product line, including HIV 1-2 SURE CHECK, a unique, easy-to-use, self-contained, single-use collection and testing device for the rapid, visual detection of antibodies to HIV 1 and HIV 2; HIV 1-2 STAT-PAK, which are easy-to-perform, single-use diagnostic tests for the rapid (15 minutes), visual detection of antibodies to HIV 1 and HIV 2 at POC; and HIV 1-2 STAT-PAK Dipstick, which are easy-to-perform, single-use diagnostic tests for the rapid, visual detection of antibodies to HIV 1 and HIV 2.

Related Links:
Chembio Diagnostics


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Hemodynamic System Monitor
OptoMonitor
New
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.